Terms/Details (Date)

Ambion Inc.*

Kreatech Biotechnology BV* (the Netherlands)

Kreatech will use Ambion technology in development of a solution for gene expression analysis

Ambion will provide its MessageAmp II a RNA amplification system under the supply agreement, terms of which were not disclosed (6/27)

Ardana plc

Cytochemia AG* (Germany)

Cytochemia got exclusive rights to market Striant SR in Germany

Striant SR is a mucoadhesive buccal testosterone treatment for hypogonadism; Ardana gets an up-front payment and ongoing suppy revenues (6/16)

Benitec Ltd.

Promega Corp.*

Promega will hold a worldwide nonexclusive license to make and sell DNA-directed RNAi- based research products

Promega will receive a cash payment and continued royalties from certain sub- licenses; the agreement is part of a settled contract dispute (8/22)

Biogen Idec

Genentech Inc.(NYSE:DNA)

Genentech is purchasing Biogen Idec's biologics for the facility, and is expected to offer manufacturing facility in Oceanside, Calif.

Genentech will pay about $408M in cash jobs to the 403 employees at the facility (6/16)

Cobra Bio-

Auxilium Pharmaceuticals Inc. (AUXL)

Cobra will manufacture and supply AA4500 for Phase II/III trials

Auxilium is developing the protein drug for Peyronie's disease and Dupuytren's disease; the value of the deal exceeds $3.3M through 2006 (8/2)

Large Scale
Biology Corp.

Planet Biotechnology Inc.*

They expanded a deal to extract and purify Planet's CaroRx

The deal expands on a July 2004 agreemment covering the plant-made antibody; terms were not disclosed (7/12)

Biologics Inc.*

Lentigen Corp.*

Omnia will provide Lentigen access to its cGMP facilities and services

The deal focuses on development of Omnia's Lentiviral vector gene delivery technology; terms were not disclosed (8/17)

Biologics Inc.*

AFG Biosolutions Inc.*

Omnia will provide AFG with manufacturing and product development services.

AFG works on products against potential biological weapons; details on the deal were not disclosed (7/19)

Tm Bioscience

InterGenetics Inc.*

Tm will supply custom Tag-It reagents to InterGenetics for OncoVue under a five-year deal

InterGenetics is expected to buy at least $7.5M in reagents over the five years; Oncovue is a genetic-based breast cancer risk test (6/30)


Paladin Labs Inc. (Canada; TSE:PLB)

Deal to commercialize Twinject in Canada

The product is an epinephrine auto-injector approved in Canada for emergency treatment of severe allergic reactions; terms of the deal were not disclosed (7/27)


* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AIM = Alternative Investment Market; ASX = Australian Stock Market; LSE = London Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange

No Comments